

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: THC BioMed Intl Ltd. (the "Issuer").

Trading Symbol: THC

Number of Outstanding Listed Securities: 100,754,960

Date: October 6, 2016

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On September 7, 2016, the Issuer announced the appointment of Hee Jung Chun, as its interim CFO, as further described in Item 2 below.

On September 12, 2016, the Issuer announced that, in connection with its agreement with Trans-Medica Ltd. ("Trans-Medica"), which was announced on July 16, 2015, it has closed a private placement (the "Private Placement"), as further described in Item 2 below.

On September 26, 2016, the Issuer announced that it has signed an LOI to purchase 100% of Clone Shipper, a US based company, as further described in Item 2 below.

THC continues to communicate with Health Canada and work toward the amendment of its license to allow it to sell starting material to registered patients under the ACMPR. THC also continues to pursue the amendment to its license that will allow it to sell dried cannabis and oil.

2. Provide a general overview and discussion of the activities of management.

On September 7, 2016, the Issuer announced the appointment of Hee Jung Chun, as its interim CFO. Hee Jung is one of the original founders of the Issuer.

Tracey St. Denis resigned from the position as CFO but remains with the Issuer as its chief accountant.

On September 12, 2016, the Issuer announced that, in connection with its agreement with Trans-Medica, which was announced on July 16, 2015, it has closed a Private Placement raising total gross proceeds of \$250,000 by the issuance of 1,000,000 common shares (the "Shares"). The Shares were issued at a price of \$0.25 per Share and are subject to a four month and one day hold period in accordance with applicable securities laws.

Trans-Medica is a private Ontario based company with extensive relationships in all aspects of the medical marijuana industry, from growth and growing systems to clinicians and prescription.

In September 2016, the Issuer accepted the exercise of common share purchase warrants for the issuance of 5,686,249 common shares for total proceeds of approximately \$1,801,387.

On September 26, 2016, the Issuer announced that it has signed an LOI to purchase 100% of Clone Shipper, a US based company, specializing in packaging products used to transport live plants, for 1 Million USD

On September 26, 2016, the Issuer announced that it has signed an LOI to purchase 100% of Clone Shipper, a US based company, specializing in packaging products used to transport live plants, for 1 Million USD.

Clone shipper is currently the only device that meets Canadian and Federal International laws governing the transportation of controlled live plants.

The Issuer intends to strengthen the patents protecting this device and will ensure that this invention is protected under international laws.

Management will continue to employ fiscal discipline as we asses and strategically move forward in building an international vertically integrated Cannabis conglomerate. Management continues to work diligently to increase shareholder value and meet the milestones it has set out to shareholders.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On September 26, 2016, the Issuer entered into an LOI to purchase 100% of Clone Shipper. Clone Shipper is not a Related Person of the Issuer.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	1,000,000	Common shares issued at a price of \$0.25 per common share.	General working capital
Common Shares	3,578,583	Warrant exercises at \$0.15 per common share.	General working capital
Common Shares	2,107,666	Warrant exercises at \$0.60 per common share.	General working capital

15. Provide details of any loans to or by Related Persons.

N/A.

16. Provide details of any changes in directors, officers or committee members.

On September 7, 2016 Hee Jung Chun was appointed as interim CFO and Tracey St. Denis resigned from her position as CFO but remains as chief accountant of the Issuer.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **October 6, 2016**_____.

John Miller
Name of Director or Senior Officer

"John Miller"
Signature

President & CEO
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/D
THC BioMed Intl Ltd.	September 2016	16/10/06
Issuer Address Suite 1100-888 Dunsmuir Street		
City/Province/Postal Code Vancouver, BC V6C 3K4	Issuer Fax No. (604) 682 1666	Issuer Telephone No. (604) 682 1643
Contact Name John Miller	Contact Position President & CEO	Contact Telephone No. (604) 682 1643
Contact Email Address info@thcbiomed.com	Web Site Address www.thcbiomed.com	